This page contains a Flash digital edition of a book.
Haemophilia


1. Gilbert MS, Musculoskeletal Complications of Haemophilia: The Joint, Haemophilia, 2000;6(Suppl. 1):34–7.


2. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R, Optimizing factor prophylaxis for the haemophilia population: where do we stand?, Haemophilia, 2004;10(Suppl. 4):97–104.


3. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al., Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia, N Engl J Med, 2007;357:535–44.


4. Gringeri A, Mantovani LG, Scalone L, Mannucci PM, Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group, Blood, 2003;102:2358–63.


5. Santagostino E, [Guidelines for the substitutive therapy of haemophilia and hereditary coagulation defects approved by the Directors of Italian Haemophilia Centres], Association of Italian Haemophilia Centres, 2003.


6. Hay CR, Baglin TP, Collins PW, et al., The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO), Br J Haematol, 2000;111:78–90.


7. Paisley S, Wight J, Currie E, Knight C, The management of inhibitors in haemophilia A: introduction and systematic review of current practice, Haemophilia, 2003;9:405–17.


8. White GC, Rosendaal F, Aledort LM, et al., Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis, Thromb Haemost, 2001;85:560.


9. Lusher JM, Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII,


Blood Coagul Fibrinolysis, 2000;11(Suppl. 1):S45–9.


10. McDonald A, Hoffman M, Hedner U, et al., Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B, J Thromb Haemost, 2007;5:1577–83.


11. Astermark J, Rocino A, von Depka M, et al., Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors, Haemophilia, 2007;13:38–45.


12. Iorio A, Matino D, D'Amico R, Makris M, Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors, Cochrane Database Syst Rev, 2010;(8):CD004449.


13. Treur MJ, McCracken F, Heeg B, et al., Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression, Haemophilia, 2009;15:420–36.


14. Astermark J, Donfield SM, DiMichele DM, et al., A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study, Blood, 2007;109:546–51.


15. Young G, Shafer FE, Rojas P, Seremetis S, Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison, Haemophilia, 2008;14:287–94.


16. Abildgaard CF, Penner JA, Watson-Williams EJ, Anti-inhibitor Coagulant Complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia, Blood, 1980;56:978–84.


17. Chuansumrit A, Isarangkura P, Angchaisuksiri P, et al., Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection, Haemophilia, 2000;6:61–5.


18. DiMichele D, Negrier C, A retrospective postlicensure survey of FEIBA efficacy and safety, Haemophilia, 2006;12:352–62.


19. Hilgartner M, Aledort L, Andes A, Gill J, Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group, Transfusion, 1990;30:626–30.


20. Kavakli K, Makris M, Zulfikar B, et al., Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross- over trial, Thromb Haemost, 2006;95:600–5.


21. Lusher JM, Roberts HR, Davignon G, et al., A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group, Haemophilia, 1998;4:790–8.


22. Santagostino E, Mancuso ME, Rocino A, et al., A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors, J Thromb Haemost, 2006;4:367–71.


23. Santagostino E, Gringeri A, Mannucci PM, Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention, Br J Haematol, 1999;104:22–6.


24. Shapiro AD, American experience with home use of NovoSeven: recombinant factor VIIa in hemophiliacs with inhibitors, Haemostasis, 1996;26(Suppl. 1):143–9.


142


EUROPEAN ONCOLOGY & HAEMATOLOGY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68